Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Actinium Pharmaceuticals

Entera Bio Ltd

In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed.

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar

SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa to Present at the Sidoti Small-Cap Investor Conference

Atossa Therapeutics Inc (NASDAQ:ATOS). (Nasdaq: ATOS) has announced its support for the SMART (Stockholm MAmmography Risk stratified Trial) study, a new Phase 2 clinical trial aimed at validating an innovative artificial intelligence-driven breast cancer risk assessment model.

Atossa Therapeutics to support AI-based breast cancer risk study

SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model is validated for therapeutic use, it could serve as the foundation for a future, Phase 3, trial investigating (Z)-endoxifen in the breast cancer prevention setting. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?

Ligand Pharmaceuticals

Solid Biosciences

Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.

3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off

Altimmune

Prime Medicine Inc

With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look at weight loss stocks, like Viking Therapeutics (NASDAQ: VKTX ), for example.

Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024

Atossa Therapeutics Inc (NASDAQ:ATOS) has given the last patient's final dose in its Karisma-Endoxifen clinical trial, aimed at reducing the chances of breast cancer. Some 240 people took part in the phase two trial, which began in November, Atossa Therapeutics said on Wednesday.

Atossa Therapeutics gives final dose in breast cancer prevention study

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company's Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics Inc (NASDAQ:ATOS) continued to advance the development of its lead clinical asset (Z)-endoxifen to prevent and treat breast cancer in the first quarter of 2024, exiting the quarter in a strong cash position with no debt. “The first quarter of 2024 was a period of significant progress for our company,” Dr Steven Quay, CEO of the clinical-stage biopharmaceutical company said in a statement.

Atossa Therapeutics maintains strong cash position while advancing breast cancer therapy in Q1

SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Standard Lithium Ltd

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.

Shhh! 3 Secret Penny Stocks Flying Below Wall Street's Radar

Atossa Therapeutics Inc (NASDAQ:ATOS) has welcomed new guidelines released by the US Preventative Services Task Force that recommend women begin breast cancer screening starting at age 40. The biopharmaceutical company targeting breast cancer with its lead asset (Z)-endoxifen highlighted that the change to the recommended age comes in response to rising breast cancer rates among younger women and racial disparities in breast cancer diagnosis and mortality.

Atossa Therapeutics welcomes updated breast cancer screening guidelines

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

Eli Lilly

Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating Atossa's lead drug candidate (Z)-endoxifen in combination with Eli Lilly and Co (NYSE:LLY)'s abemaciclib (VERZENIO) in women with Estrogen Receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The clinical-stage biopharmaceutical company said the new study arm would enroll approximately 20 women newly diagnosed with ER+/HER2- invasive breast cancer.

Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drug

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company's leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled encouraging safety and efficacy findings from its Phase 2 EVANGELINE clinical trial evaluating (Z)-endoxifen as a neoadjuvant therapy for breast cancer. Data presented at the American Association for Cancer Research (AACR) Annual Meeting showed that six out of seven individuals displayed Ki-67 levels below 10%, indicating favorable responses to treatment.

Atossa Therapeutics reports positive data from breast cancer treatment trial

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Atossa Therapeutics Inc (NASDAQ:ATOS) told investors it ended 2023 with $88.5 million in cash and cash equivalents and no debt as it advanced its investigational therapeutic (Z)-endoxifen, which is targeting breast cancer and other breast conditions. For the year ended December 31, 2023, Atossa spent $17.3 million on research and development, including spending on clinical and non-clinical trials and drug development costs for (Z)-endoxifen.

Atossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestones

SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent Company developments. Atossa is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer and other breast conditions.

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Inc (NASDAQ:ATOS) shares continued to move higher on Wednesday, buoyed by the news that a patient with pre-menopausal breast cancer had successfully completed a five-year treatment using its investigative breast cancer therapy (Z)-endoxifen. Shares of the biotechnology company added 5% at $1.63 late morning Wednesday.

News for Atossa Genetics Stock (ATOS)